1. Scrip
  2. >>R&D
  3. >>Clinical Trials

ESMO 23: MARIPOSA Data Blunt J&J’s Rybrevant Threat To Tagrisso

 
• By Alexandra Shimmings

Decidedly mixed data from the MARIPOSA study released early from the ESMO meeting suggest that Johnson & Johnson’s Rybrevant poses less of a threat to AstraZeneca’s best-selling drug, Tagrisso, than had been mooted. More data on safety and overall survival should prove telling.    

LungCancerCells_1200x675

AstraZeneca PLC’s market-leading position in advanced non-small cell lung cancer market with Tagrisso is looking a little more assured following the early release of all late-breaking abstracts from this weekend’s European Society for Medical Oncology meeting in Madrid.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D